Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.001
Neutral
RSI(14)
45.818
Neutral
STOCH(KDJ)(9,3,3)
29.182
Sell
ATR(14)
0.159
High Vlolatility
CCI(14)
-46.295
Neutral
Williams %R
64.815
Sell
TRIX(12,20)
0.185
Sell
StochRSI(14)
6.506
Sell
Search
Tempest Therapeutics Inc
TPSTAdd to Watchlist
1.830USD
-0.260-12.44%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
26.25MMarket Cap
0.06P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Tempest Therapeutics Inc
Currency: USD Updated: 2026-05-15Key Insights
Tempest Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 114 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Tempest Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Tempest Therapeutics Inc Highlights
StrengthsRisks
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Overvalued
The company’s latest PE is 0.06, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.51M shares, increasing 44.27% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
11.000
Target Price
+426.32%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Tempest Therapeutics Inc is 6.98, ranking 146 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.10
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.03
Tempest Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Tempest Therapeutics Inc is 8.64, ranking 31 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is 0.06, which is 14.26% below the recent high of 0.06 and 101873.24% above the recent low of -57.81.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 114/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Tempest Therapeutics Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 9.00 and a low of 9.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
11.000
Target Price
+426.32%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Tempest Therapeutics Inc
TPST
1
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Tempest Therapeutics Inc is 6.08, ranking 286 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.13 and the support level at 1.59, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.924
Sell
MA10
1.986
Sell
MA20
1.910
Sell
MA50
1.949
Sell
MA100
2.285
Sell
MA200
5.347
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Tempest Therapeutics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 31.43%, representing a quarter-over-quarter increase of 278.70%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Tempest Therapeutics Inc is 1.53, ranking 294 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is -1.74. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
-1.77
VaR
+9.50%
240-Day Maximum Drawdown
+87.15%
240-Day Volatility
+99.61%
Return
Best Daily Return
60 days
+29.75%
120 days
+29.75%
5 years
+3972.98%
Worst Daily Return
60 days
-19.65%
120 days
-23.26%
5 years
-59.26%
Sharpe Ratio
60 days
-0.47
120 days
-1.36
5 years
+0.40
Risk Assessment
Maximum Drawdown
240 days
+87.15%
3 years
+98.80%
5 years
+99.26%
Return-to-Drawdown Ratio
240 days
-0.83
3 years
-0.30
5 years
-0.20
Skewness
240 days
-1.21
3 years
+26.75
5 years
+34.45
Volatility
Realised Volatility
240 days
+99.61%
5 years
+166.16%
Standardised True Range
240 days
+23.42%
5 years
+185.30%
Downside Risk-Adjusted Return
120 days
-186.79%
240 days
-186.79%
Maximum Daily Upside Volatility
60 days
+100.60%
Maximum Daily Downside Volatility
60 days
+74.89%
Liquidity
Average Turnover Rate
60 days
+4.69%
120 days
+3.96%
5 years
--
Turnover Deviation
20 days
-93.90%
60 days
-92.95%
120 days
-94.04%
Peer Comparison
Biotechnology & Medical Research
Tempest Therapeutics Inc
TPST
6.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
